1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
TaiGen Biopharmaceuticals Holdings Limited

TaiGen Biopharmaceuticals Holdings Limited

TTPEX:4157
8.85
TWD
-0.13
(-1.45%)
0.22EPS
39.37P/E
6.13BMarket Cap
Nov 18Next Earn
TaiGen Biopharmaceuticals Holdings Limited
TPEX:4157
(Taipei Exchange)

Recent

price

8.85

P/E

ratio

39.37

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
0.72
0.74
0.07
0.11
0.15
0.11
0.2
0.77
0.04
0.03
0.03
1.81
0.05
0.17
0.21
0.36
0.36
Revenue per Share
-110.9
0.14
-0.81
-0.66
-0.58
-0.59
-0.35
1.04
-0.48
-0.41
-0.56
1.08
-0.33
0.19
-0.05
0.06
0.22
Basic EPS, GAAP
-10.1
-1.28
-0.27
-0.72
-0.79
-0.87
-0.23
-0.39
-0.39
-0.48
-0.35
0.86
-0.04
- -
-0.25
0.02
0.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-7.48
0.88
0.58
0.23
1.22
0.63
0.94
1.99
1.53
1.14
0.62
1.75
1.35
1.56
1.51
1.51
1.44
Book Value per Share
-7.78
0.82
0.53
0.18
1.17
0.57
0.89
1.93
1.47
1.09
0.57
1.72
1.34
1.54
1.49
1.48
1.38
Tangible Book Value per Share
21
304
590
654
698
697
714
717
717
717
717
717
717
717
717
716
709
Basic Weighted Avg Shares
15
226
40
70
105
78
146
553
30
20
23
1,295
36
123
151
259
256
Sales/Revenue/Turnover
-3,026.19
-95.64
-1,234.82
-710.67
-388.73
-552.8
-162.79
47.08
-872.43
-1,364.25
-1,312.1
69.48
-766.41
-141.88
-81.05
26.74
32.24
Operating Margin (%)
29
23
12
10
9
10
9
10
11
34
31
29
29
28
25
17
11
Depreciation Expense
-2,286
43
-478
-432
-404
-413
-250
746
-343
-296
-405
776
-237
137
-39
45
155
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
11.46
- -
4.71
- -
21.35
6.92
Effective Tax Rate (%)
-15,333.54
18.98
-1,182.47
-618.52
-385.97
-529.45
-171.23
134.92
-1,158.79
-1,455.57
-1,728.37
59.92
-654.61
111.04
-25.61
17.41
60.49
Profit Margin (%)
-4,468
462
491
240
888
426
636
1,002
760
615
297
1,142
898
1,062
1,040
1,037
971
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
17
- -
35
17
59
42
9
6
LT Debt
-4,289
508
368
154
852
442
676
1,424
1,093
815
442
1,254
970
1,119
1,082
1,075
1,022
Total Equity
- -
11.42
- -
- -
- -
- -
- -
24.8
- -
- -
- -
88.76
- -
-15.1
- -
4.87
7.61
Return on Invested Capital (%)
- -
-2.27
- -
- -
- -
- -
- -
71.08
- -
- -
- -
87.84
- -
12.52
- -
4.1
14.91
Return on Capital (%)
- -
- -
-109.21
-165.62
-80.27
-63.84
-44.76
71.08
-27.26
-30.99
-64.39
91.47
-21.33
13.09
-3.51
4.19
15.55
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
41
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
9
7
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
712
712
712
Market Capitalization
9,539
7,901
6,129

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,120
1,047
1,002
Cash, Cash Equivalents & STI
1,027
961
915
Accounts Receivable, Net
5
4
9
Inventories
76
71
70
Total Current Liabilities
83
54
31
Payables & Accruals
- -
- -
- -
ST Debt
41
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.17%
34.46%
-0.69%
Free Cash Flow
-27,120.22%
-54,239.51%
-109.34%
Net Income, GAAP
-148.6%
-185.03%
-217.09%
Sales/Revenue/Turnover
591.95%
1,132.84%
72.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10
121
9
10
151
2025
11
11
7
231
259
2026
10
8
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
0.09
-0.1
-0.03
-0.05
2025
-0.03
-0.17
-0.02
0.29
0.06
2026
-0.02
-0.03
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) develops novel therapeutics for infectious diseases and other indications with high unmet medical needs. The Taiwan-based biopharmaceutical company, founded in 2001 and headquartered at 7F, No. 138, Xinming Rd., Neihu Dist., Taipei City 11470, Taiwan, focuses on anti-infective agents through internal research and in-licensed programs; its core pipeline includes Taigexyn (nemonoxacin), a non-fluorinated quinolone antibiotic targeting community-acquired pneumonia (oral and IV formulations), diabetic foot infections, nosocomial pneumonia, urinary tract infections, and complicated skin infections, with approvals in Taiwan, marketing authorization in Russia, and NDA filings in Malaysia and China; TG-1000, a single-dose influenza antiviral for influenza A/B (adult/adolescent and pediatric formulations) and avian influenza H7N9, advancing through Phase III completion, NDA submission in mainland China, and pediatric IND submission; Furaprevir, an HCV protease inhibitor for chronic hepatitis C alone or combined with Imitasvir; and Burixafor, a stem cell mobilizer for stem cell transplantation and chemosensitization. TaiGen operates primarily in the biotechnology sector, serving global markets in Asia (Taiwan, China, Malaysia, Russia), the US, and beyond through subsidiaries like TaiGen Biopharmaceuticals Co. (Beijing) Ltd.; it also provides pharmaceutical technology consulting and health food manufacturing/sales. Recent developments encompass exclusive license agreements with YSP in 2023 and Joincare for TG-1000 in China; completion of TG-1000 Phase III enrollment and study in 2024; NDA submission for TG-1000 in mainland China and Taigexyn in Malaysia during 2024; pediatric formulation IND submission for TG-1000 in China and expansion into Vietnam with Taigexyn licensing in 2025; and new single-dose flu drug targeting global markets as of early 2025.